Slide 1: Exchange filing cover letter: Investor Presentation
30th October, 2025 (1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code:
Slide 2: Investor Presentation Q2FY26
Investor Presentation Q2FY26 30-10-2025 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Highest-Ever Quarterly Revenue at INR 7,500+ Cr with Robust Profitability
Highest-Ever Quarterly Revenue at INR 7,500+ Cr with Robust Profitability Revenue EBITDA PAT 8% INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr 4% (YoY) Q2FY26 INR 7,589 Cr (YoY) 25% 18% of Revenue of Revenue Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR 3,146 C
Slide 5: Financial Performance – Q2FY26
Financial Performance – Q2FY26 Revenue INR 7,589 Cr EBITDA INR 1,895 Cr Revenue1 Break-up Q2FY26 (Consolidated) API, 2% Others, 1% Actuals vs Q2 FY25 (INR Cr) Emerging Markets & Europe, 13% Total Revenue from 7,589 7.6% Operations One India, EBITDA 1,895 0.5% 41% EBITDA % 25.0% One Africa, 16% PAT 1
Slide 6: One India - Committed to Sustainable Progress and Enduring Impact
One India1 - Committed to Sustainable Progress and Enduring Impact Delivered a Revenue of INR 3,146 Cr in Q2 FY26 Branded Prescription Trade Generics Consumer Health ❖ Business delivered a strong growth ❖ Cipla maintained #2 market2 rank during the quarter ❖ Delivered a robust growth with in overall
Slide 7: India Rx - Strengthening Our Journey with Strategic Therapeutic Focus
India Rx - Strengthening Our Journey with Strategic Therapeutic Focus Steady Uptake in Key Therapies1 Growth (%) Largest pharma company by Volume Respiratory 8% (units) in market1 8% Anti-infectives 4% 7% 4 Brands added in the category of market1 Urology 12% 17% revenue > INR 100 Cr YoY Anti-diabete
Slide 8: Unlocking Growth in Chronic Care: Cipla–Eli Lilly Collaboration
Unlocking Growth in Chronic Care: Cipla–Eli Lilly Collaboration Key Highlights Market Impact & Accessibility • Agreement Type: Promotion and Distribution • Expanded Reach: Partnership extends Tirzepatide availability beyond cities with Eli Lilly’s existing • Product: Yurpeak (Tirzepatide) presence •
Slide 9: Empowering the Fight Against AMR: Cipla's Stewardship
Empowering the Fight Against AMR: Cipla’s Stewardship CLICK TO EDIT MASTER TITLE STYLE Huena Zemdri Cipenmet (Methenamine Hippurate) (Plazomicin) (Novel anti-infective) ❑ Cipla introduces HUENA® – India’s ❑ Cipla strengthens fight against ❑ Cipla partners with Orchid Pharma to first non-antibiotic d
Slide 10: Q2 FY26 - Global Consumer Wellness Franchise
Q2 FY26 - Global Consumer Wellness Franchise One India One Africa Consumer brands in 1 One India 2 Revenue: INR 404 Cr Pain Relief Nicotine Pain Replacement Respi OTC Management 2 2 Consumer brands in Hydration Cold & Cough South Africa Cold & Cough Respi OTC Revenue: ZAR 437 Mn 2 Skin Infection Res
Slide 11: North America - Witnessed Continuous Traction in Key Differentiated Assets
North America - Witnessed Continuous Traction in Key Differentiated Assets Key Business Highlights • Albuterol ranked No. 1 in market1 with share increased to 22% (50 million+ inhaler units supplied to the U.S. market cumulatively) • Lanreotide market2 share increased to 22% during the quarter • Lau
Slide 12: ANDA & NDA Portfolio & Pipeline (As on 30th September 2025)
ANDA & NDA Portfolio & Pipeline (As on 30th September 2025) 7 66 9 2 98 2 15 1 4 22 39 20 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 180 45 60 285 Approved Tentatively Under Approval Total ANDAs & NDAs Approved
Slide 13: One Africa - South Africa Private Growing 1.3x Faster than the Market
One Africa1 - South Africa Private Growing 1.3x Faster than the Market ZAR Mn SA Private Revenue trend 21 23 11 1,398 9 1,341 20 23 1,197 75 80 Q2FY25 Q2FY26 Q2FY24 Q2FY25 Q2FY26 SA Private SA Tender North Africa Others (SSA & CGA) Market Segment 2 Rank Share Cipla Growth Market Growth SA Key Highli
Slide 14: Q2FY26 - Emerging Markets & Europe and API
Q2FY26 - Emerging Markets & Europe and API Emerging Markets & Europe API Revenue Revenue 19 110 17 96 Q2FY25 Q2FY26 Q2FY25 Q2FY26 13
Slide 15: Q2FY26: Progress on ESG goals (India Manufacturing Operations)
Q2FY26: Progress on ESG goals (India Manufacturing Operations) Goals (India Manufacturing Operations by 2025) Progress as on YTD Aug 2025 80% reduction in absolute Scope 1 (energy based) and 76% reduction from the baseline year, YTD Aug 2019 Scope 2 emissions from baseline year of FY 2019-20 Water n
Slide 16: Consolidated Profit and Loss Statement Summary
INR Cr Consolidated Profit and Loss Statement Summary Particulars Q2 FY26 Q2 FY25 Revenue from sale of products 7,447 6,961 Other operating income 142 90 Income from operations 7,589 7,051 Material cost 2,498 2,283 Employee benefits expense 1,315 1,208 Other expenses 1,882 1,675 Total expenses 5,695
Slide 17: Consolidated Balance Sheet
Consolidated Balance Sheet INR Cr Key Balance Sheet Items Sep-25 Sep-24 Equity 33,025 28,456 Total Debt# 467 461 Inventory 6,160 5,573 Cash and Cash Equivalents* 10,368 8,412 Trade Receivables 6,902 5,588 Trade Payables 3,035 2,675 Net Tangible Assets 6,996 6,329 Goodwill and Intangibles 5,374 5,111
Slide 18: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 17